Merck & Co. offers steady income stream to investors with strong drug portfolio and dividend growth.

From Yahoo Finance: 2025-06-28 02:15:00

Merck & Co., Inc. (NYSE:MRK) is a top pharmaceutical company known for Keytruda, a leading cancer drug. In 2024, MRK expanded its drug portfolio with strategic acquisitions. The company has a strong pipeline, including new treatments like Winrevair. With 14 years of dividend growth, MRK offers a reliable income stream to investors.

While MRK is a solid investment, some AI stocks may offer higher potential returns. For those seeking undervalued AI stocks, a free report is available. Check out other investment options like the “10 Best Dividend Stocks for a Bear Market” and “10 Best Dividend Stocks for Dependable Dividend Growth.” No disclosures.

Read more: Should You Count on MRK for Steady Passive Income?